Erythropoietin is associated with an increased risk of adverse cardiovascular complications in patients with kidney disease if it is used to target an increase of hemoglobin levels above 13.0 g/dl.
A eritropoetina está asociada cun incremento do risco de complicacións cardiovasculares en pacientes con doenzas renais se é usada para aumentar os niveis de hemoglobina por riba de 13,0 g/dl.